scy-635 profile

ID Source	ID
PubMed CID	6479267
CHEMBL ID	1269597
SCHEMBL ID	23924210
MeSH ID	M0539933

Synonym
cyclo[[(e)-(2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-l-2-aminobutyryl-[(2r)-2-{[2-(dimethylamino)ethyl]thio}-2-(methylamino)acetyl]-4-hydroxy-n-methyl-l-leucyl -l-valyl-n-methyl-l-leucyl-l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucy
[(2r)-2-{[2-(dimethylamino)ethyl]thio}-2-(methylamino)acetyl]3-[4-hydroxy-n2-methyl-l-leucyl]4csa
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-(2-dimethylaminoethylsulfanyl)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methyl-hex-4-enyl]-24-(2-hydroxy-2-methyl-propyl)-6,9,18-triisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,2
scy-635
bdbm50136473
chembl1269597 ,
scy 635
cyclosporin a, 8-((2r)-2-((2-(dimethylamino)ethyl)thio)-n-methylglycine)-9-(4-hydroxy-n-methyl-l-leucine)-
wsu5343074 ,
unii-wsu5343074
210759-10-7
DB12451
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-[2-(dimethylamino)ethylsulfanyl]-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,
Q27292806
SCHEMBL23924210
(3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-27-{[2-(dimethylamino)ethyl]sulfanyl}-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-bis(propan-2-yl)-1,

Excerpt	Reference	Relevance
" SCY-635 was shown to be orally bioavailable in multiple animal species and produced blood and liver concentrations of parent drug that exceeded the 50% effective dose determined in the bicistronic con1b-derived replicon assay."	( SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Erdmann, F; Fischer, G; Harris, R; Hopkins, S; Huang, Z; Murray, MG; Ribeill, Y; Scorneaux, B; Smitley, C; Wring, S, 2010)	2.71

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Transthyretin	Homo sapiens (human)	Ki	0.0018	0.0018	0.0022	0.0026	AID496160
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7740	10.0000	AID496042
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	58.5000	0.0001	1.7536	10.0000	AID496039
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.0151	10.0000	AID496043
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	13.4000	0.0000	2.8005	10.0000	AID496041
Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)	IC50 (µMol)	0.0103	0.0088	0.0095	0.0103	AID528323
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	12.4000	0.0000	2.3983	10.0000	AID496040
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	IC50 (µMol)	0.7792	0.0020	0.1438	1.5490	AID528322; AID95464
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Ki	0.0018	0.0003	0.0473	0.2310	AID496160
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	0.0450	0.0001	1.0768	10.0000	AID197947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)	Kd	0.0029	0.0010	0.0053	0.0098	AID1168835
Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)	Kd	0.0031	0.0010	0.0028	0.0042	AID1168836
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Kd	0.0032	0.0022	0.4297	6.4200	AID1168824
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
signal transduction	Transthyretin	Homo sapiens (human)
purine nucleobase metabolic process	Transthyretin	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
regulation of post-translational protein modification	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation of multicellular organism growth	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral process	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral genome replication	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein stabilization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
bone development	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
response to ischemia	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of proton-transporting ATPase activity, rotational mechanism	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of ATP-dependent activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of mitochondrial membrane permeability	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial depolarization	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
necroptotic process	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to hydrogen peroxide	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to arsenic-containing substance	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cellular response to calcium ion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondria	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of oxidative phosphorylation	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
skeletal muscle fiber differentiation	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in programmed necrotic cell death	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial outer membrane permeabilization involved in programmed cell death	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of oxidative phosphorylation uncoupler activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein kinase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
apoptotic process	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
viral release from host cell	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neuron differentiation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
leukocyte chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
activation of protein kinase B activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of stress-activated MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
lipid droplet organization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cellular response to oxidative stress	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein dephosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
endothelial cell activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein secretion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cell adhesion molecule production	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein K48-linked ubiquitination	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet aggregation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of viral life cycle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
hormone activity	Transthyretin	Homo sapiens (human)
protein binding	Transthyretin	Homo sapiens (human)
identical protein binding	Transthyretin	Homo sapiens (human)
thyroid hormone binding	Transthyretin	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
collagen binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA polymerase binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
peptide binding	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
integrin binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
virion binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
heparan sulfate binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
azurophil granule lumen	Transthyretin	Homo sapiens (human)
extracellular exosome	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum lumen	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
smooth endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
melanosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
perinuclear region of cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum chaperone complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
intracellular membrane-bounded organelle	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
mitochondrial proton-transporting ATP synthase complex	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrial permeability transition pore complex	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
mitochondrion	Peptidyl-prolyl cis-trans isomerase F, mitochondrial	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
extracellular region	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular space	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
vesicle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
secretory granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
ficolin-1-rich granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (169)

Assay ID	Title	Year	Journal	Article
AID496064	Cmax in monkey at 1.4 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496053	Induction of CYP2B6 in human hepatocytes at 0.1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496013	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1178327	Antiviral activity against HCV infected in human patient assessed as log reduction in plasma viral RNA at 300 mg dosed three times daily	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID496011	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 24 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496038	Half life in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID528325	Antiviral activity against HCV after 72 hrs by stable luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID496070	Systemic clearance in Sprague-Dawley rat at 2 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496144	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication at 0.02 to 5 uM after 24 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496095	AUC (0 to infinity) in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496063	Cmax in Sprague-Dawley rat at 5 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496082	Cmax in Sprague-Dawley rat at 20 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496060	Induction of CYP3A4 in human hepatocytes at 1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496152	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by RT-PCR analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496153	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 120 hrs by RT-PCR analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496067	Apparent volume of distribution in Sprague-Dawley rat at 5 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496032	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496150	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 24 hrs by RT-PCR analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496042	Inhibition of human recombinant CYP1A2 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496087	Cmax in monkey at 7.5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496092	Tmax in monkey at 15 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496114	AUC (2 to 24 hrs) in Sprague-Dawley rat liver at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496078	AUC (0 to infinity) in Sprague-Dawley rat at 2 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496065	Cmax in monkey at 1 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496112	AUC (2 to 24 hrs) in Sprague-Dawley rat liver at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496159	Inhibition of calcineurin phosphatase activity of CyPA up to 2 uM	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496061	Induction of CYP3A4 in human hepatocytes at 15 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496037	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as suppression of full length viral RNA replication after 24 to 72 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496121	Cmax in Sprague-Dawley rat whole blood at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496162	Ratio of compound EC50 to cyclosporine A EC50 for inhibition of anti-CD3/CD28 antibody-induced IL-2 production in human Jurkat cells	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496136	Ratio of Cmin in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496326	AUC (2 to 24 hrs) in Sprague-Dawley rat whole blood at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496151	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 48 hrs by RT-PCR analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496157	Selectivity index, ratio of CC50 for human Huh7 cells to EC50 for Hepatitis C virus infected in human Huh7ET cells	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496036	Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release up to 10 uM after 72 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496068	Apparent volume of distribution in monkey at 1.4 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496164	Cytotoxicity against human PBMC at 0.0031 uM after 18 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496154	Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release after 72 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496086	Cmax in Sprague-Dawley rat at 10 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496122	Cmax in Sprague-Dawley rat whole blood at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496080	AUC (0 to infinity) in monkey at 1.4 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496015	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay in presence of 10% human serum	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496115	AUC (2 to 24 hrs) in Sprague-Dawley rat whole blood at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID528323	Binding affinity to cyclophilin B by ELISA	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID496075	Apparent elimination half life in Sprague-Dawley rat at 5 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496084	Cmax in monkey at 15 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496089	Tmax in Sprague-Dawley rat at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496012	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496076	Apparent elimination half life in monkey at 1.4 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496035	Half life in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496111	Oral bioavailability in monkey at 7.5 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496119	Cmax in Sprague-Dawley rat liver at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496163	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496137	Ratio of Cmin in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496143	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 120 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496074	Apparent elimination half life in Sprague-Dawley rat at 2 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496104	Apparent elimination half life in monkey at 15 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496126	Cmin in Sprague-Dawley rat liver at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496108	Oral bioavailability in Sprague-Dawley rat at 20 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496113	AUC (2 to 24 hrs) in Sprague-Dawley rat liver at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID528322	Binding affinity to cyclophilin A by ELISA	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID496155	Cytotoxicity against human Huh7 cells assessed as lactate dehydrogenase release after 72 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496103	Apparent elimination half life in monkey at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496019	Antiinflammatory activity in human Jurkat cells assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496081	AUC (0 to infinity) in monkey at 1 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496094	AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496117	AUC (2 to 24 hrs) in Sprague-Dawley rat whole blood at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496146	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication at 0.02 to 5 uM after 72 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496167	Ratio of compound EC50 to cyclosporine A EC50 for inhibition of anti-CD3/CD28 antibody-induced IL-2 production in human PBMC	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496161	Cytotoxicity against human Jurkat cells at 9.9 uM after 18 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496102	Apparent elimination half life Sprague-Dawley rat at 20 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496129	Cmin in Sprague-Dawley rat whole blood at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496072	Systemic clearance in monkey at 1.4 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496139	Cellular uptake in human hepatocytes assessed per mg of cellular protein association with nonparenchymal fraction at 0.378 uM after 1 hr by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496127	Cmin in Sprague-Dawley rat whole blood at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496088	Tmax in Sprague-Dawley rat at 5 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496048	Induction of CYP1A2 in human hepatocytes at 1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496100	Apparent elimination half life Sprague-Dawley rat at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496027	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 15 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496118	Cmax in Sprague-Dawley rat liver at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496135	Ratio of Cmax in whole blood to liver in Sprague-Dawley rat at 30 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496041	Inhibition of human recombinant CYP2C9 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496093	Tmax in monkey at 7. 5 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168837	Antiviral activity against HCV subtype 1a in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496049	Induction of CYP1A2 in human hepatocytes at 15 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496055	Induction of CYP2B6 in human hepatocytes at 15 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496016	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay in presence of 20% human serum	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496109	Oral bioavailability in monkey at 5 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496166	Cytotoxicity against human PBMC assessed as cell viability at 10 uM after 18 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496071	Systemic clearance in Sprague-Dawley rat at 5 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496066	Apparent volume of distribution in Sprague-Dawley rat at 2 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496132	Ratio of AUC (2 to 24 hrs) in whole blood to liver in Sprague-Dawley rat at 30 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496123	Cmax in Sprague-Dawley rat whole blood at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496098	AUC (0 to infinity) in monkey at 15 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496099	AUC (0 to infinity) in monkey at 7.5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496040	Inhibition of human recombinant CYP2C19 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496142	Cellular uptake in human hepatocytes assessed per mg of cellular protein association with hepatocyte fraction at 2.27 uM after 1 hr by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496043	Inhibition of human recombinant CYP2D6 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496024	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496125	Cmin in Sprague-Dawley rat liver at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496133	Ratio of Cmax in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID95464	Immunosuppressive activity was measured by inhibition of the IL-2 production in Jurkat cells.	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.
AID496147	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication at 0.02 to 5 uM after 120 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496052	Induction of CYP2B6 in human hepatocytes at 10 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID528324	Immunosuppressive activity against human Jurkat cells assessed as inhibition of phytohemagglutinin-M/phorbol myristate acetate-induced IL2 production	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID496145	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication at 0.02 to 5 uM after 48 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496134	Ratio of Cmax in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1178326	Inhibition of MRP2 (unknown origin) assessed as reduction in pump efflux activity	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID496130	Ratio of AUC (2 to 24 hrs) in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168838	Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene in presence of 40% human serum	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496148	Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release up to 5 uM after 72 hrs in presence of 10 to 40% human serum	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID762653	Antiviral activity against HIV1 LAI infected in human CEM4 cells assessed as inhibition of viral replication	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID762649	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells after 72 hrs by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID496091	Tmax in monkey at 5 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496022	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496033	Intrinsic clearance in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496039	Inhibition of human recombinant CYP3A4 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496029	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 1 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496097	AUC (0 to infinity) in monkey at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID528326	Cytotoxicity against human HuH7 cells assessed as release of lactate dehydrogenase	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID1168839	Cytotoxicity against human MT4 cells by CDCF probe based assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID1168840	Cytotoxicity against PHA-stimulated human PBMC by 5-bromo-2'-deoxyuridine incorporation assay	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496120	Cmax in Sprague-Dawley rat liver at 30 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496023	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 15 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496124	Cmin in Sprague-Dawley rat liver at 10 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496034	Intrinsic clearance in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID197947	In vitro inhibitory activity against HIV-1 RT in CEM4 cell line	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.
AID1168825	Antiviral activity against HCV subtype 1b in human Huh7.5 cells expressing subgenomic HCV replicons and coexpressing luciferase reporter gene	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496020	Plasma protein binding in human after 30 min by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496083	Cmax in Sprague-Dawley rat at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496160	Inhibition of calcineurin phosphatase activity of CyPA	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496101	Apparent elimination half life Sprague-Dawley rat at 10 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496017	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay in presence of 40% human serum	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496073	Systemic clearance in monkey at 1 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496085	Cmax in monkey at 5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496156	Selectivity index, ratio of CC50 for human Huh7ET cells to EC50 for Hepatitis C virus infected in human Huh7ET cells	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496014	Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release up to 5 uM after 72 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168835	Binding affinity to human cyclophilin B by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496058	Induction of CYP3A4 in human hepatocytes at 10 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168836	Binding affinity to human cyclophilin F by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496062	Cmax in Sprague-Dawley rat at 2 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496106	Oral bioavailability in Sprague-Dawley rat at 5 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496107	Oral bioavailability in Sprague-Dawley rat at 10 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496149	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication at 0.02 to 5 uM by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496025	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 1 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496059	Induction of CYP3A4 in human hepatocytes at 0.1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496046	Induction of CYP1A2 in human hepatocytes at 10 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168824	Binding affinity to human cyclophilin A by surface plasmon resonance method	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496140	Cellular uptake in human hepatocytes assessed per mg of cellular protein association with hepatocyte fraction at 0.378 uM after 1 hr by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496141	Cellular uptake in human hepatocytes assessed per mg of cellular protein association with nonparenchymal fraction at 2.27 uM after 1 hr by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496030	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496131	Ratio of AUC (2 to 24 hrs) in whole blood to liver in Sprague-Dawley rat at 10 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496128	Cmin in Sprague-Dawley rat whole blood at 10 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496090	Tmax in Sprague-Dawley rat at 20 mg/kg, po by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496054	Induction of CYP2B6 in human hepatocytes at 1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496079	AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496105	Apparent elimination half life in monkey at 7.5 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496251	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 15 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496047	Induction of CYP1A2 in human hepatocytes at 0.1 uM after 72 hrs relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496028	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1168827	Kinetic solubility of the compound in pH 7.0 water	2014	Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20	Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
AID496021	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 1 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496138	Ratio of Cmin in whole blood to liver in Sprague-Dawley rat at 30 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1178325	Inhibition of Pgp (unknown origin) assessed as reduction in pump efflux activity	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID496069	Apparent volume of distribution in monkey at 1 mg/kg, iv after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496096	AUC (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, po after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496026	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496077	Apparent elimination half life in monkey at 1 mg/kg, iv by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID496110	Oral bioavailability in monkey at 15 mg/kg after 24 hrs by LC/MS/MS analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (15.38)	29.6817
2010's	11 (84.62)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (7.69%)	5.53%
Reviews	2 (15.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (76.92%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
adenine [no description available]	2.11	1	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytosine [no description available]	2.11	1	aminopyrimidine; pyrimidine nucleobase; pyrimidone	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3-methylcholanthrene Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.	2.05	1	ortho- and peri-fused polycyclic arene	aryl hydrocarbon receptor agonist; carcinogenic agent
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	2.05	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.11	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.05	1	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.05	1	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.11	1	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.11	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
ribavirin Rebetron: Rebetron is tradename	3.18	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	2.11	1	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.11	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
erlotinib hydrochloride [no description available]	2.11	1	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
organophosphonates hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.	2.11	1	divalent inorganic anion; phosphite ion
cmx 001 [no description available]	2.11	1
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	8.15	5	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
su 11248 [no description available]	2.11	1	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
sanglifehrin a sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source	2.48	2
n-methyl-valyl-4-cyclosporin a N-methyl-valyl-4-cyclosporin A: a cyclosporin A analog	2.08	1
(melle-4)cyclosporin (melle-4)cyclosporin: a non-immunosuppressive analog of cyclosporin A	4.94	6
galidesivir [no description available]	2.11	1
cyclosporine metabolite m17 cyclosporin A metabolite M17 : A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol. It specifically inhibits growth of renal cells in culture.	2.08	1	cyclosporin A derivative; primary allylic alcohol	drug metabolite
alisporivir alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source	4.94	6	homodetic cyclic peptide	anticoronaviral agent
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.05	1	benzenes; hydroxycoumarin; methyl ketone
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	4.59	4
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	2.05	1	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	4.71	6	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	1	11.71	6	0
Ebola Hemorrhagic Fever [description not available]	0	2.11	1	0
Communicable Diseases, Emerging Infectious diseases that are novel in their outbreak ranges (geographic and host) or transmission mode.	0	2.11	1	0
Break-Bone Fever [description not available]	0	2.11	1	0
Dengue An acute febrile disease transmitted by the bite of AEDES mosquitoes infected with DENGUE VIRUS. It is self-limiting and characterized by fever, myalgia, headache, and rash. SEVERE DENGUE is a more virulent form of dengue.	0	2.11	1	0
Hemorrhagic Fever, Ebola A highly fatal, acute hemorrhagic fever caused by EBOLAVIRUS.	0	2.11	1	0
Chronic Hepatitis C [description not available]	0	4.37	1	1
Hepatocellular Carcinoma [description not available]	0	4.37	1	1
Cancer of Liver [description not available]	0	4.37	1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	4.37	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	0	4.37	1	1
Hepatitis C, Chronic INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.	1	6.37	1	1

scy-635

Cross-References

Synonyms (16)

Research Excerpts

Bioavailability

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (109)

Molecular Functions (57)

Ceullar Components (30)

Bioassays (169)

Research

Studies (13)

Market Indicators

Research Demand Index: 19.57

Study Types

scy-635

Cross-References

Synonyms (16)

Research Excerpts

Bioavailability

Protein Targets (11)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (109)

Molecular Functions (57)

Ceullar Components (30)

Bioassays (169)

Research

Studies (13)

Market Indicators

Research Demand Index: 19.57

Study Types

Related Drugs (26)

Related Conditions (13)